[Clinical usefulness of tumor markers for the diagnosis of ovarian cancer]. 1992

K Ito, and Y Udagawa, and S Nozawa
Dept. of Obstetrics and Gynecology, School of Medicine, Keio University, Japan.

The most useful diagnostic methods for ovarian cancer at present are diagnostic imaging and measurement of tumor markers. Although many tumor markers have been measured to detect patients with ovarian cancer, the values of diagnostic efficiency are not so high when a single tumor marker is assessed. Therefore, the use of a combination of tumor markers might be expected to yield a higher value. In this study, tumor markers were measured to select an ovarian cancer group from a group in which ovarian tumor was palpable by the pelvic examination. We selected CA 602 from core-protein related markers, CA 54/61 from sugar chain core-related markers, and galactosyltransferase associated with tumor (GAT) for their combined use from among eleven markers examined. As a result, the combined use of each two markers or of all three markers appeared to be beneficial to discriminate ovarian cancers from benign ovarian tumors. The combination of all three markers gave a somewhat higher positive rate and diagnostic efficiency value than that of the two markers. The role of tumor markers in the future screening of ovarian cancer was also discussed in this paper.

UI MeSH Term Description Entries
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011933 Reagent Kits, Diagnostic Commercially prepared reagent sets, with accessory devices, containing all of the major components and literature necessary to perform one or more designated diagnostic tests or procedures. They may be for laboratory or personal use. Diagnostic Reagent Kits,Diagnostic Reagents and Test Kits,Diagnostic Test Kits,In Vitro Diagnostic Device,In Vitro Diagnostic Devices,In Vitro Diagnostic Medical Device,In Vitro Diagnostic Medical Devices,Kits, Diagnostic Reagent,Diagnostic Reagent Kit,Diagnostic Test Kit,Kit, Diagnostic Reagent,Kit, Diagnostic Test,Kits, Diagnostic Test,Reagent Kit, Diagnostic,Test Kit, Diagnostic,Test Kits, Diagnostic
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D005260 Female Females
D005700 Galactosyltransferases Enzymes that catalyze the transfer of galactose from a nucleoside diphosphate galactose to an acceptor molecule which is frequently another carbohydrate. EC 2.4.1.-. Galactosyltransferase
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015295 Antigens, Tumor-Associated, Carbohydrate Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies. Antigens, Carbohydrate, Tumor-Associated,CA Antigens,Cancer-Associated Carbohydrate Antigens,Carbohydrate Antigens, Tumor-Associated,Tumor-Associated Carbohydrate Antigens,Antigen, Carcinoma-Associated,CA Antigen,CA(Oxford) Antigen,Carcinoma-Associated Antigen,Epitectin,Antigen, CA,Antigen, Carcinoma Associated,Antigens, CA,Antigens, Cancer-Associated Carbohydrate,Antigens, Tumor-Associated Carbohydrate,Cancer Associated Carbohydrate Antigens,Carbohydrate Antigens, Cancer-Associated,Carbohydrate Antigens, Tumor Associated,Carcinoma Associated Antigen,Tumor Associated Carbohydrate Antigens

Related Publications

K Ito, and Y Udagawa, and S Nozawa
October 1993, Rinsho byori. The Japanese journal of clinical pathology,
K Ito, and Y Udagawa, and S Nozawa
April 1997, Journal of chemotherapy (Florence, Italy),
K Ito, and Y Udagawa, and S Nozawa
January 2016, Ginekologia polska,
K Ito, and Y Udagawa, and S Nozawa
March 2014, Indian journal of cancer,
K Ito, and Y Udagawa, and S Nozawa
January 1979, International advances in surgical oncology,
K Ito, and Y Udagawa, and S Nozawa
February 1994, Rinsho byori. The Japanese journal of clinical pathology,
K Ito, and Y Udagawa, and S Nozawa
July 2004, Gan to kagaku ryoho. Cancer & chemotherapy,
K Ito, and Y Udagawa, and S Nozawa
April 2023, Clinical chemistry and laboratory medicine,
K Ito, and Y Udagawa, and S Nozawa
March 2011, Collegium antropologicum,
K Ito, and Y Udagawa, and S Nozawa
March 1994, Obstetrics and gynecology clinics of North America,
Copied contents to your clipboard!